Latest Content

The phase 3 MINT trial found inebilizumab significantly reduced exacerbations and rescue therapy use in patients with generalized myasthenia gravis.

In this analysis, all 4 biologic classes showed reduced risk, and the CV benefit remained consistent across White, Black, and Asian patients.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and insurance-driven prescribing decisions.

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data.

A 4-million-person study finds unvaccinated COVID-19 infection raises myocarditis, pericarditis, and death risk far more than the Pfizer vaccine.

Atlanta clinicians described obesity care that stalls between routine diagnosis and delayed treatment, with coverage rules driving therapy choices.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.